Format

Send to

Choose Destination
Int J Cancer. 2018 Jan 15;142(2):414-423. doi: 10.1002/ijc.31061. Epub 2017 Oct 12.

Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.

Zeitoun JD1,2,3,4, Baron G1,4,5, Vivot A1,4, Atal I1,4, Downing NS6, Ross JS7,8,9,10, Ravaud P1,4,5,11.

Author information

1
Centre d'Épidémiologie Clinique, Hôpital Hôtel Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.
2
Gastroenterology and Nutrition, Hôpital Saint-Antoine, Assistance Publiques-Hôpitaux de Paris, Paris, France.
3
Proctology, Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, France.
4
INSERM UMR 1153, Centre de Recherche Épidémiologie et Statistique Paris Sorbonne Cité (CRESS), METHODS Team, Paris, France.
5
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
6
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
7
Department of Internal Medicine, Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, Connecticut, USA.
8
Department of Internal Medicine, Section of General Internal Medicine, Yale School of Medicine, New Haven, CT.
9
Department of Health Policy and Management, Yale School of Public Health, New Haven, CT.
10
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT.
11
Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY.

Abstract

Post-marketing research in oncology has rarely been described. We aimed to characterize post-marketing trials for a consistent set of anticancer agents over a long period. We performed a cross-sectional analysis of post-marketing trials registered at ClinicalTrials.gov through September 2014 for novel anticancer agents approved by both the US Food and Drug Administration and the European Medicines Agency between 2005 and 2010. All relevant post-marketing trials were classified according to indication, primary outcome, starting date, sponsors, and planned enrollment. Supplemental indications were retrieved from regulatory documents and publication rate was assessed by two different methods. Ten novel anticancer agents were eligible: five were indicated for hematologic malignancies and the remaining five for solid cancers (three for kidney cancer). We identified 2,345 post-marketing trials; 1,362 (58.1%) targeted an indication other than the originally approved one. We observed extreme variations among drugs in both number of post-marketing trials (range 8-530) and overall population to be enrolled per trial (1-8,381). Post-marketing trials assessed almost all types of cancers, the three most frequently studied cancers being leukemia, kidney cancer and myeloma. In all, 6.6% of post-marketing trials had a clinical endpoint as a primary outcome, and 35.9% and 54.1% had a safety or surrogate endpoint, respectively, as a primary outcome. Nine drugs obtained approval for supplemental indications. The publication rate at 10 years was 12.3 to 26.1% depending on the analysis method. In conclusion, we found that post-marketing research in oncology is highly heterogeneous and the publication rate of launched trials is low.

KEYWORDS:

anticancer agents; outcome; post-marketing trials; publication rate

PMID:
28929484
DOI:
10.1002/ijc.31061
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center